Laser Processing and Plasmonics Laboratories, Department of Engineering Physics, École Polytechnique de Montréal, P.O. Box 6079, Downtown Station, Montréal, Québec, H3C 3A7, Canada.
J Control Release. 2011 Feb 10;149(3):273-80. doi: 10.1016/j.jconrel.2010.10.034. Epub 2010 Oct 31.
Nanonization is a simple and effective method to improve dissolution rate and oral bioavailability of drugs with poor water solubility. There is growing interest to downscale the nanocrystal production to enable early preclinical evaluation of new drug candidates when compound availability is scarce. The purpose of the present study was to investigate laser fragmentation to form nanosuspensions in aqueous solution of the insoluble model drug megestrol acetate (MA) using very little quantities of the drug. Laser fragmentation was obtained by focusing a femtosecond (fs) or nanosecond (ns) laser radiation on a magnetically stirred MA suspension in water or aqueous solution of a stabilizing agent. The size distribution and physicochemical properties of the drug nanoparticles were characterized, and the in vitro dissolution and in vivo oral pharmacokinetics of a laser fragmented formulation were evaluated. A MA nanosuspension was also prepared by media milling for comparison purpose. For both laser radiations, smaller particles were obtained as the laser power was increased, but at a cost of higher degradation. Significant nanonization was achieved after a 30-minfs laser treatment at 250mW and a 1-hns laser treatment at 2500mW. The degradation induced by the laser process of the drug was primarily oxidative in nature. The crystal phase of the drug was maintained, although partial loss of crystallinity was observed. The in vitro dissolution rate and in vivo bioavailability of the laser fragmented formulation were similar to those obtained with the nanosuspension prepared by media milling, and significantly improved compared to the coarse drug powder. It follows that this laser nanonization method has potential to be used for the preclinical evaluation of new drug candidates.
纳米化是一种提高药物水溶性差的药物溶解速率和口服生物利用度的简单有效方法。当化合物可用性稀缺时,人们越来越有兴趣将纳米晶体生产规模缩小,以能够对新的候选药物进行早期临床前评估。本研究的目的是调查激光破碎法在水相中形成难溶性模型药物醋酸甲地孕酮(MA)纳米混悬剂的方法,该方法只需使用少量药物。通过将飞秒(fs)或纳秒(ns)激光辐射聚焦在水或稳定剂的水溶液中的 MA 混悬液上,可以获得激光破碎。对药物纳米颗粒的粒径分布和物理化学性质进行了表征,并对激光破碎制剂的体外溶解和体内口服药代动力学进行了评价。还制备了 MA 纳米混悬剂用于比较目的。对于两种激光辐射,随着激光功率的增加,可以获得更小的颗粒,但代价是更高的降解。在 250mW 的 fs 激光处理 30 分钟和 2500mW 的 ns 激光处理 1 小时后,实现了显著的纳米化。药物激光处理过程引起的降解主要是氧化性质的。尽管观察到部分结晶度丧失,但药物的晶体相得以保持。激光破碎制剂的体外溶解速率和体内生物利用度与通过介质研磨制备的纳米混悬剂相似,并且与粗药物粉末相比显著提高。因此,这种激光纳米化方法有可能用于新候选药物的临床前评估。